Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
6%
Antiangiogenic
5%
Bevacizumab
21%
Binimetinib
10%
Biological Marker
17%
Capecitabine
14%
Cetuximab
34%
Chemotherapy
26%
Colorectal Carcinoma
44%
Cross-Sectional Study
10%
DNA Topoisomerase
10%
Encorafenib
10%
Epidermal Growth Factor Receptor
12%
Epirubicin
10%
Irinotecan
21%
Long Term Survival
10%
Malignant Neoplasm
17%
Metastatic Colorectal Cancer
100%
microRNA
21%
Neoplasm
18%
Overall Survival
27%
Oxaliplatin
65%
Pancreas Cancer
11%
Peritoneum Metastasis
21%
Primary Tumor
12%
Progression Free Survival
8%
Regorafenib
5%
Systemic Treatment
5%
Tipiracil
5%
Tissue Inhibitor of Metalloproteinase
10%
Trifluridine
5%
Urokinase Receptor
10%
Medicine and Dentistry
Abdominal Cancer
16%
Adverse Event
6%
Antiangiogenic
5%
Arm
12%
Bevacizumab
10%
Biological Marker
15%
Biopsy Technique
13%
Cancer Cell
12%
Capecitabine
10%
Chemotherapy
66%
Cisplatin
5%
Colon Carcinoma
10%
Colorectal Carcinoma
39%
Doxorubicin
5%
Epidermal Growth Factor Receptor
8%
Epirubicin
10%
Gastrectomy
10%
Gene Amplification
10%
Gene Fusion
5%
Immunotherapy
7%
Irinotecan
15%
Long Term Survival
10%
Metalloprotease Inhibitor
10%
Metastatic Colorectal Cancer
52%
microRNA
10%
Molecular Profiling
5%
Neoplasm
18%
Ovarian Cancer
10%
Overall Survival
6%
Oxaliplatin
29%
Pancreas Cancer
22%
Pembrolizumab
10%
Peritoneum Metastasis
52%
Recurrent Disease
10%
Regorafenib
5%
Surgery
5%
Systemic Therapy
5%
Tipiracil
5%
Topoisomerase
10%
Trifluridine
5%
Tumor Biology
5%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
10%
Cancer Cell
30%
Capecitabine
12%
Colon
5%
DNA Methylation
10%
DNA Topoisomerase
10%
Drug Resistance
12%
Epirubicin
10%
Gene Amplification
10%
KRAS
10%
MAP2K6
10%
Metalloprotease Inhibitor
10%
MicroRNA
21%
TOP2A
10%
Topoisomerase
10%